News | November 06, 2024
Granules India Q2 FY25 PAT drops 5% YoY to Rs. 97 Cr
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24
He has 35+ years of experience in understanding of business and products, analytical ability, eye for detail and computer literacy and knowledge of recent trends.
The newly setup entity, Emcutix Biopharmaceuticals Limited, plans to significantly expand Emcure’s offerings
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
Strengthening focus in Alzheimer's disease and neuroscience pipeline
Lupin's R&D teams are working on products with a near-zero global warming potential propellant
Our China operations continue under the leadership of the current General Manager of AstraZeneca China
Subscribe To Our Newsletter & Stay Updated
